Donating plasma helps people with rare diseases, chronic immune disorders, bleeding conditions, severe burns, certain neurological diseases, and high-risk pregnancies. For many of these patients, therapies made from donated plasma are the only available treatment. Plasma is the liquid portion of blood, rich in proteins like antibodies, clotting factors, and albumin, and each of these proteins can be separated and turned into a specific medicine for a specific group of patients.
People With Weakened Immune Systems
One of the largest groups that depends on donated plasma is people born with primary immunodeficiency disorders. These are genetic conditions where the body produces little or no antibodies, leaving a person vulnerable to repeated, serious infections. Their immune systems simply cannot fight off bacteria and viruses the way a healthy person’s can.
Donated plasma from hundreds or even thousands of donors is pooled and processed into a concentrated antibody product. When infused into a patient’s bloodstream, these borrowed antibodies neutralize bacterial toxins and viruses, essentially standing in for the immune protection the patient’s body can’t create on its own. Patients typically receive infusions every few weeks to keep their protective antibody levels high enough to prevent infections. The broader the pool of donors, the wider the range of antibodies in each dose, which means better coverage against more pathogens.
People With Bleeding Disorders
Hemophilia A and hemophilia B are conditions where the blood is missing a specific clotting protein, which means even minor injuries can cause prolonged or dangerous bleeding. Plasma contains the full set of clotting factors, and manufacturers can extract and concentrate the specific ones these patients need. The clotting proteins are freeze-dried, tested, and treated to eliminate potential viruses before being packaged for use.
Other bleeding and clotting disorders also rely on plasma-derived treatments. Von Willebrand disease, the most common inherited bleeding disorder, and antithrombin III deficiency, a condition that increases the risk of dangerous blood clots, are both managed with proteins sourced from donated plasma.
Burn Victims and Trauma Patients
Severe burns trigger massive fluid shifts in the body. Fluid leaks out of blood vessels into surrounding tissue, causing dangerous swelling, dropping blood pressure, and starving organs of oxygen. Albumin, a protein extracted from donated plasma, helps counteract this by pulling fluid back into the bloodstream through its natural water-attracting properties.
In clinical studies of burn patients, albumin infusion was associated with reduced mortality and an 81% decrease in the odds of compartment syndrome, a painful and limb-threatening complication caused by extreme tissue swelling. Patients who received albumin also had lower rates of kidney dysfunction, respiratory complications, sepsis, and tissue death. For trauma patients and people undergoing major surgery, albumin serves a similar role: maintaining blood volume and preventing shock when the body is losing fluid rapidly.
People With Neurological Diseases
Several rare neurological conditions respond to plasma-based therapies. Chronic inflammatory demyelinating polyneuropathy (CIDP) is a progressive disease where the immune system attacks the insulation around peripheral nerves, leading to weakness and paralysis in the arms and legs. Because the damage is driven by rogue antibodies, two plasma-based approaches can help.
The first is plasma exchange, where a patient’s own plasma is physically removed and replaced, stripping out the harmful antibodies. Clinical trials show this produces significant short-term improvement in disability and nerve function, though patients may need repeated rounds. The second is infusing concentrated antibodies from donor plasma, which works by modulating the immune system and dampening the autoimmune attack. Myasthenia gravis, a condition causing severe muscle weakness, and Guillain-Barré syndrome, a rapid-onset paralysis, are treated with similar strategies.
People With Alpha-1 Lung Disease
Alpha-1 antitrypsin deficiency is a genetic condition where the body doesn’t produce enough of a protective protein that shields the lungs from damage. Without it, enzymes released by white blood cells slowly destroy lung tissue, leading to early-onset emphysema. Smoking dramatically accelerates this process.
The only disease-modifying treatment is a weekly infusion of the missing protein, purified from donated plasma. This therapy has proven clinical efficacy in slowing the decline of lung function. Patients receive it for life, meaning a steady, ongoing supply of donated plasma is essential to keep their lungs functioning.
Pregnant Women With Rh Incompatibility
When a pregnant woman has Rh-negative blood and her baby has Rh-positive blood, her immune system can recognize the baby’s blood cells as foreign and produce antibodies against them. This is called Rh sensitization, and it can cause severe anemia or even death in the baby during the current or future pregnancies.
A plasma-derived product called Rho(D) Immune Globulin prevents this. It is manufactured from the plasma of Rh-negative donors who have been immunized with Rh-positive red blood cells. Given at around 26 to 28 weeks of pregnancy and again within 72 hours of delivery, it reduces the rate of Rh sensitization to just 0.1 to 0.2%. It is also used after miscarriage, ectopic pregnancy, amniocentesis, and abdominal trauma during pregnancy. Before this product existed, Rh disease was a leading cause of newborn illness and death.
People Exposed to Rabies or Tetanus
Plasma donations are also processed into targeted treatments for specific infections. If someone is bitten by an animal that may carry rabies, they receive rabies immune globulin, a concentrated dose of anti-rabies antibodies derived from donor plasma. This provides immediate, short-term protection while the person’s own immune system responds to the rabies vaccine. A similar product exists for tetanus, giving exposed patients ready-made antibodies to neutralize the toxin.
Patients in Infectious Disease Outbreaks
During epidemics, plasma from people who have recovered from an infection contains antibodies that can help those still fighting it. This approach, called convalescent plasma therapy, has been used successfully against influenza, SARS, MERS, Ebola, Argentine hemorrhagic fever, and COVID-19. It has also historically been deployed against hepatitis, mumps, polio, and measles. While not always a first-line treatment, convalescent plasma serves as a bridge therapy when no vaccine or targeted drug is yet available, reducing viral loads and improving survival in some patients.
Why Demand Is So High
What makes plasma donation different from whole blood donation is scale. Many of these therapies require plasma pooled from large numbers of donors to produce a single treatment course. A patient with a primary immunodeficiency needs infusions every few weeks, indefinitely. A patient with Alpha-1 lung disease needs weekly infusions for life. A single person with hemophilia may require hundreds of donations’ worth of clotting factor in a single year. Because plasma-derived therapies are the only option for many of these conditions, the supply depends entirely on people willing to donate regularly.